Huashen Zhiyao Technology

Huashen Pharmaceutical is a prominent Chinese biopharmaceutical company and a core subsidiary of the publicly traded Huashen Technology Group. The company integrates research, development, and manufacturing, focusing on both innovative biological drugs and modernized Traditional Chinese Medicine (TCM). Its flagship product, Licartin (Iodine[131I] Metuximab Injection), is a pioneering radioimmunotherapy specifically approved for the treatment of primary hepatocellular carcinoma. Additionally, the company maintains a strong market presence in cardiovascular and respiratory health with products like Sanchitongshu Capsules and Biyuanshu Oral Liquid. Huashen operates high-standard GMP manufacturing bases and continues to expand its pipeline in oncology and chronic disease sectors.